Abstract
Background HIV prevention through pre-exposure prophylaxis (PrEP) may encourage riskier sexual behaviours that undermine the protection afforded by PrEP and generates negative spillovers on sexually transmitted diseases. Tests for such risk compensatory behaviour in high-risk populations, such as the female sex workers (FSW) in Senegal we studied, are lacking. Methods We stratified the sample by self-reported sexual risk-taking and prior PrEP experience and randomly assigned them to PrEP referral in October 2021-January 2022 (treatment, n=300) or to deferred PrEP referral after the endline survey in April-May 2022 (control, n=200). We randomised 500 FSWs to start PrEP and included 308 FSWs in the final analysis (T=182, C=126). We compared outcomes in the period preceding PrEP referral of the control group. The primary outcome was self-reported condom use with clients. Secondary outcomes were self-reported sexual risk taking, number of clients, proportion of regular clients, perceived HIV risk of clients, and type of sex act. We estimated intention-to-treat effects of PrEP referral and both average treatment effects on the treated and local average treatment effects of PrEP utilisation. The trial is registered with ISRCTN (ISRCTN16445862). Findings PrEP referral increased the probability of using PrEP by 34.5 percentage points (pp) [95% CI: 25.4, 43.6; p<0.0001, control group mean: 11.1%]. Estimated effects of PrEP referral and PrEP use on condom use with the last client were 3.3 pp [95% CI: -4.0, 10.6; p=0.376] and 7.9 pp [95% CI: -10.4, 26.3; p=0.397 respectively (control group mean: 84.9%). When looking at condom use with all last three clients, these effects were 11.0 pp [95% CI: 0.8, 21.1; p=0.034] and 25.8 [95% CI: 5.2, 46.4] respectively (control group mean: 67.5%) There were no notable effects on other risky behaviours. Interpretation This randomised experiment did not give strong grounds for concerns that PrEP encouraged sexual risk-taking by FSWs, at least in the short-term. Robustness of this finding should be tested in larger, longer-term studies and in other contexts. Whether PrEP users are more likely to overreport condom use than non-PrEP users should also be further investigated.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ISRCTN16445862
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UCL ethics committee and Senegal national ethics committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All files are available from the UCL repository database.